|
| Interactions: | AtorvastatinAdverse Effect: an increased risk of myopathy or rhabdomyolysisClinical Management: If concurrent therapy is required, monitor the patient for signs and symptoms of myopathy or rhabdomyolysis.
GlibenclamideAdverse Effect: HypoglycemiaClinical Management: If concurrent therapy is required, monitor the patients blood glucose carefully. A reduction in the dose of glyburide may be required.
Lovastatin Adverse Effect: an increased risk of myopathy or rhabdomyolysisClinical Management: The combined use of gemfibrozil and statins should generally be avoided. If concurrent therapy is required, monitor the patient for signs and symptoms of myopathy or rhabdomyolysis
Pravastatin sodiumAdverse Effect: Significant decrease in urinary excretion and protein binding of Pravastatin& increase in AUC, Cmax, and Tmax for the pravastatin metabolite SQ 31,906Clinical Management: Avoid concomitant administration of these drugs.
SimvastatinAdverse Effect: an increased risk of myopathy or rhabdomyolysisClinical Management: The combined use of gemfibrozil and statins should generally be avoided. If concurrent therapy is required, monitor the patient for signs and symptoms of myopathy or rhabdomyolysis
WarfarinAdverse Effect: An increased risk of bleedingClinical Management: In patients receiving warfarin and gemfibrozil concurrently, the prothrombin time ratio or international normalized ratio (INR) should be monitored to assess the anticoagulant response. The warfarin dosage may need to be adjusted with the addition and withdrawal of gemfibrozil and periodically during concurrent therapy to maintain the desired level of anticoagulation. |
|
|